METHOD OF ESTIMATING THE CLINICAL EFFECTIVENESS OF TRIFLUOPERAZINE FOR TREATING DISORDERS ACCOMPANYING DEVELOPING PSYCHOTIC SYMPTOMS

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to pharmacogenetics, clinical pharmacology, psychiatry, addictology, and can be used for selecting a dose of antipsychotic drug trifluoperazine in the patients. That is ensured by genotyping using polymorphic markers of CYP1A2 genes. That is followed by calculating the value of the parameter P, which is the estimated value of the change in the rate of biotransformation trifluoperazine, depending on the state of genetic polymorphism in each specific patient. If parameter P is in interval [50;∞) (deviation of biotransformation speed trifluoperazine by 50 % and higher) is recommended to replace the drug. If parameter P is in interval (-50;0) (deceleration of biotransformation speed trifluoperazine less than by 50 %) recommendation is given on dose reduction. If parameter P is in interval (0;50) (acceleration of biotransformation speed trifluoperazine recommendation for dose increase is given less than by 50 %).;EFFECT: method has high accuracy, information content and objectivity.;1 cl, 1 tbl